Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer

@article{Kim2016PrognosticallyDS,
  title={Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer},
  author={Yun Yeong Kim and H. Park and K. Lee and Kwan Il Kim and Y. Chun},
  journal={Journal of Breast Cancer},
  year={2016},
  volume={19},
  pages={163 - 168}
}
Purpose The aim of this retrospective study was to investigate whether there are prognostically different subgroups among patients with pathologic N3 (pN3) breast cancer. Methods The records of 220 patients who underwent surgery for pN3 breast cancer from January 2006 to September 2012 were reviewed. All patients received adjuvant therapy according to standard protocols. The primary outcome was disease-free survival (DFS). Results Patients were followed for a median time of 68.3 months after… Expand
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology
TLDR
It was shown that intrinsic subtype has a greater prognostic impact in predicting clinical outcomes in subpopulations of patients with stage I–III breast cancer who show discordance between stage and biologic subtypes. Expand
Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era.
TLDR
Breast cancer subtypes are still prognostic for patients with pN3 breast cancer, and pT stage, breast cancer subtype, and breast cancer stage remained significant independent factors for disease free survival. Expand
Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3.
TLDR
This nomogram accurately and reliably predicted the OS of patients with pN3 breast cancer, demonstrating better prediction capacity in OS than that of the seventh edition American Joint Committee on Cancer TNM staging classification. Expand
Metastatic axillary node ratio predicts recurrence and poor long-term prognosis in patients with advanced stage IIIC (pN3) breast cancer
  • M. Hur, S. Ko
  • Medicine
  • Annals of surgical treatment and research
  • 2017
TLDR
The data suggest that the mALNR is an independent risk factor of recurrence and mortality, and is a valuable prognostic factor to predict the long-term prognosis of stage IIIC breast cancer patients. Expand
The Challenge of pN3 Stage in Breast Cancer
TLDR
Since 1959 the American Joint Committee on Cancer (AJCC) TNM system has been used to stage breast cancer, but several publications in the last years report that there are other predictive factors that influence the prognosis, measured by the overall survival or the DFS, as much as the TNM stage does. Expand
Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients
TLDR
Higher NLR was correlated to poor prognosis of breast cancer patients and might be a potential predictor in patients’ survival to assist with physicians’ treatment decisions. Expand
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review
TLDR
A systematic overview of the published data evaluating NLR as a prognostic factor or predictive factor for pathological complete response (PCR) and toxicity in early and advanced BC found that some data showed that IBM could be predictive of chemotherapy-related toxicity. Expand
Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer
TLDR
Preoperative NLR and dNLR may be effective predictive biomarkers for prognosis in patients with BC and may be helpful to identify the patients who may benefit from the surgery, according to a meta-analysis. Expand
Breast cancer prognostication with neutrophil–lymphocyte ratio and platelet–lymphocyte ratio
TLDR
Both NLR and PLR are independently associated with an increased risk of Defensive Functioning Scale in BC and were independent, unfavorable prognostic factors in BC. Expand
Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
TLDR
PLR was found as an independent prognostic factor for survival, while NLR was an independent predictive factor for febrile neutropenia in patients with early breast cancer receiving neo adjuvant chemotherapy. Expand
...
1
2
...

References

SHOWING 1-10 OF 25 REFERENCES
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology
TLDR
It was shown that intrinsic subtype has a greater prognostic impact in predicting clinical outcomes in subpopulations of patients with stage I–III breast cancer who show discordance between stage and biologic subtypes. Expand
Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?
TLDR
The prognosis of BC patients with N3a disease has changed favorably in the past decade with the current standards of care and Her-2 status and the number of lymph nodes had significant impact on disease-free survival. Expand
Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer
TLDR
Preoperative NLR is an independent predictor of DFS in breast cancer patients, especially in triple-negative subtype, and further studies are required to validate the prognostic value of NLR before clinical application. Expand
Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
TLDR
Ki-67 expression in breast cancer tissue may be an effective factor for predicting the response to neoadjuvant chemotherapy, and it is suggested that a 25% level of Ki-67expression is a reasonable cutoff value for predicting a response to chemotherapy. Expand
Is there any Prognostically Different Subgroup among Patients with Stage IIIC (Any TN3M0) Breast Carcinoma?
TLDR
Patients with T1,2,3N3M0 disease can be divided into prognostically different subgroups according to the number of metastatic lymph nodes in the axilla and the nodal ratio; in this way, different patient subgroups may be offered different treatment strategies. Expand
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
TLDR
TNBC with high Ki-67 was associated with a more aggressive clinical feature despite a higher pCR rate, and high proliferation index Ki- 67 can be used for further classification of TNBC into two subtypes with different responses and prognosis. Expand
Personalizing breast cancer staging by the inclusion of ER, PR, and HER2.
TLDR
The internationally recognized and easily reproducible examination of ER, PR, and HER2 status exemplifies how nonanatomic factors can improve the prognostic accuracy of breast cancer staging. Expand
Comparison of Different Trials of Adjuvant Chemotherapy in Stage II Breast Cancer Using a Natural History Data Base
TLDR
The use of a NHDB and known pretreatment characteristics, such as nodal status and tumor size, permits comparison of patients at similar risk of recurrence of breast cancer who have received adjuvant chemotherapy and provides leads for evaluation in future prospective clinical trials. Expand
The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients
TLDR
The present study shows that the pre-treatment derived neutrophil-to-lymphocyte ratio is an independent prognostic factor that could be useful for future individual risk assessment in breast cancer patients. Expand
Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy.
AIMS The American Joint Committee on Cancer staging system for breast carcinomas has been revised. According to this revised staging system, metastasis to infraclavicular lymph nodes and number ofExpand
...
1
2
3
...